N/A N=12 Impact of CPAP Level on V/Q Mismatch in Premature Infants
Infant, Premature, Diseases · Respiratory Insufficiency Syndrome of Newborn
Primary: Ventilation/Perfusion Mismatch — 1.2 difference in right shift (kPa) — p=0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=154 Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
Osteoarthritis
Primary: Number of Participants With Surgeon's Assessment of Procedural Difficulty — 9; 49; 8; 66 Participants
Phase 4 N=119 SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)
Diabetes Mellitus
Primary: Glycosylated Hemoglobin A1c (HbA1c) — 6.78 percentage of <HbA1c>
Phase 3 N=141 Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
Parkinson Disease, Off Episodes
Primary: Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part…
Phase 3 N=3,324 Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel
Contraception
Primary: 6-Month (183 Days) Cumulative Pregnancy Percentage — 10.0; 10.5 pregnancy percentage
N/A N=230 PREMIUM Migraine Trial
Migraine Headaches · Patent Foramen Ovale
Primary: Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months. — 32; 38 percentage of…
N/A N=1,432 Rural Engagement in Primary Care for Optimizing Weight Reduction
Obesity
Primary: Mean Weight Change Over 24 Months; Unadjusted Except for Affiliation — -5.73; -8.34; -7.72; -3.35 kg — p=.025
Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Phase 4 N=60 Theracal Pulpotomy in Primary Molars
Deep Caries
Primary: Clinical Examination — 30; 30 Participants
Phase 2 N=48 Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
Nausea and Vomiting, Postoperative · Nausea With Vomiting Chemotherapy-Induced
Primary: Cmax — 37.282; 41.108 ng/mL
Phase 1 N=9 Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
Lung Cancer · Metastatic Cancer
Primary: The Number of Patients With a Response (Complete Response and Partial Response) — 8 Participants
Phase 4 N=485 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
Actinic Keratosis (AK)
Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects
Phase 1 N=21 Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants
Phase 3 N=175 Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score During Week 8 — -3.8; -2.8; -3.2; -1.9 score on a scale — p=<0.001
Phase 2 N=31 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Progression-Free Survival (PFS) at 4 Months — 52.17 percentage of patients alive